BioSpace News Archive

Social reform to eliminate health disparities is necessary so that Black people, the most vulnerable group for advanced colorectal cancer, get the care they need for a disease that is curable if caught early, says City of Hope expert

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.

With a shared commitment to transforming the healthcare experience, The Ohio State University Wexner Medical Center, one of the nation’s top-ranked academic health centers, and One Medical, a leading national technology-powered primary care organization, will partner to deliver seamless coordinated care in Columbus and the central Ohio region.

Genova Diagnostics has partnered with Rocky Mountain Analytical, a subsidiary of LifeLabs and leading provider of naturopathic and functional medicine, in a new distribution agreement.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has closed its previously announced registered direct offering to certain institutional investors of 8,865,000 shares of common stock at a price of $0.79 per share.

Replica Analytics, a leading provider of privacy protective synthetic data, is proud to announce that it received over $1 million in new pre-seed funding.

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences

Reneo Pharmaceuticals announced today that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products has granted the company orphan drug designation for REN001, an investigational medicine in development for the treatment of LCHAD deficiency, a fatty acid oxidation disorder (FAOD), and MELAS syndrome, a primary mitochondrial myopathy (PMM).

Kit Check™, the leader in automated and intelligent medication management solutions, today announced that it has signed an agreement with SCA Pharma that allows SCA to add an embedded RFID tag to all of its products. SCA Pharma, an FDA registered 503B entity, will be the first 503B partner to utilize Kit Check’